The study was initiated by researchers at Michigan Technological University.
Researchers unveiled a potential route for reducing the formation of peptides into plaques known to cause neurodegenerative diseases.
In their findings, researchers comprehensively examined the accuracy and efficacy of biomarkers for the diagnosis of Alzheimer's, after reviewing three separate tests.
In the new study, it is the first time that the genetic-based system was utilized to identify changes in the production of amyloid-beta.
For the study, researchers examined patterns of protein expressed in over 2,000 human brain and close to 400 cerebrospinal fluid samples belonging to individuals with and without the presence of neurodegeneration.
According to their findings, a correlation between MBI and early Alzheimer's disease pathology was demonstrated for the first time through a set of cognitive assessments and brain imaging tests.
The findings were part of the Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study, an ongoing prevention trial with a primary objective of probing normal older adults with increased brain amyloid.
In their new study, released online in the peer-reviewed journal Nature, low-density lipoprotein receptor-related protein 1 (LRP1) was linked to the uptake and spread of tau in the brain.